Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHDN 2022

What's new?

View all
3:35
Symptoms of juvenile onset Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022
2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
1:34
EHDN 2022 meeting highlights
Patrick Weydt • 23 Sep 2022

Latest in the HD therapeutic pipeline

View all
5:38
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease
Michael Hayden • 27 Sep 2022
2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022

Hot topics: biomarkers

View all
2:06
Advancing mHTT as a biomarker in Huntington’s disease
Lauren Byrne • 23 Sep 2022
3:32
NfL as a potential biomarker for juvenile onset Huntington’s disease
Lauren Byrne • 23 Sep 2022

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals